A carregar...
SUN-348 Cabozantinib in Advanced Adrenocortical Carcinoma: Rationale and Protocol of Two Phase II Clinical Trials
BACKGROUND: Median overall survival (OS) in advanced adrenocortical (ACC) is only 12-15 months. Mitotane and chemotherapy are the backbones of current treatment but prolonged disease stabilization is rare. Cabozantinib (CABO) is an oral multi-kinase inhibitor (MKI) of c-MET, VEGFR2, AXL, and RET. OB...
Na minha lista:
| Publicado no: | J Endocr Soc |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Endocrine Society
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6553301/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-348 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|